Q2 EPS Estimates for Aurora Cannabis Reduced by Roth Capital

Key Points

• Roth Capital has lowered its Q2 2026 earnings estimate for Aurora Cannabis from $0.23 to $0.12 per share, while the current full-year consensus estimate stands at $0.46 per share.
• Aurora Cannabis reported a loss of $0.19 per share for its latest quarter, significantly missing the consensus estimate of $0.18, and posted revenues of $71.98 million which fell short of the expected $96.83 million.
• Following the adjustments in earnings estimates, Wall Street Zen downgraded Aurora's shares from "hold" to "sell," reflecting a cautious outlook on the company's performance.

Aurora Cannabis Inc. (NASDAQ:ACB - Free Report) - Roth Capital dropped their Q2 2026 earnings per share estimates for shares of Aurora Cannabis in a research report issued to clients and investors on Wednesday, August 6th. Roth Capital analyst W. Kirk now forecasts that the company will post earnings per share of $0.12 for the quarter, down from their previous estimate of $0.23. The consensus estimate for Aurora Cannabis' current full-year earnings is $0.46 per share. Roth Capital also issued estimates for Aurora Cannabis' Q3 2026 earnings at $0.59 EPS and Q4 2026 earnings at ($0.09) EPS.

Other research analysts also recently issued reports about the company. Zacks Research upgraded Aurora Cannabis to a "strong sell" rating in a research note on Friday, August 8th. Wall Street Zen downgraded Aurora Cannabis from a "hold" rating to a "sell" rating in a research note on Friday, July 18th. Two analysts have rated the stock with a sell rating, one has assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, Aurora Cannabis has a consensus rating of "Moderate Buy".

Aurora Cannabis Stock Performance

Shares of ACB stock traded down $0.14 during midday trading on Monday, hitting $5.25. The company had a trading volume of 522,026 shares, compared to its average volume of 1,905,799. The company's 50 day simple moving average is $4.78 and its 200 day simple moving average is $4.83. Aurora Cannabis has a 52-week low of $3.42 and a 52-week high of $7.05. The stock has a market cap of $296.53 million, a price-to-earnings ratio of -27.65 and a beta of 1.84. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.97 and a quick ratio of 1.51.

Aurora Cannabis (NASDAQ:ACB - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of $0.18 by ($0.37). Aurora Cannabis had a negative return on equity of 1.49% and a negative net margin of 5.66%. The firm had revenue of $71.98 million for the quarter, compared to analyst estimates of $96.83 million.

Institutional Trading of Aurora Cannabis

A number of institutional investors have recently modified their holdings of ACB. Renaissance Technologies LLC boosted its stake in shares of Aurora Cannabis by 8.6% in the fourth quarter. Renaissance Technologies LLC now owns 714,655 shares of the company's stock valued at $3,037,000 after buying an additional 56,400 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Aurora Cannabis by 7.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 84,921 shares of the company's stock worth $361,000 after purchasing an additional 5,800 shares in the last quarter. Susquehanna Fundamental Investments LLC purchased a new stake in Aurora Cannabis during the fourth quarter worth $45,000. Bulltick Wealth Management LLC purchased a new stake in Aurora Cannabis during the fourth quarter worth $150,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in Aurora Cannabis during the fourth quarter worth $221,000. 47.63% of the stock is currently owned by hedge funds and other institutional investors.

Aurora Cannabis Company Profile

Aurora Cannabis Inc, together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada.